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“coronavirus disease 2019” (COVID-19) [3]. 
The Coronaviridae Study Group (CSG) of 
the International Committee on Taxonomy 
of Viruses (ICTV) has renamed the previ-
ously provisionally named 2019-nCoV as 
“severe acute respiratory syndrome corona-
virus-2” (SARS-CoV-2) [4]. The human-
to-human transmission of SARS-CoV-2 is 
presumed to be primarily through droplets 
and fomites.
R0, used to measure the transmission po-
tential of a communicable disease in epide-
miology, is the average number of secondary 
infections produced by an infectious case in 
a population where everyone is susceptible 
[5]. Early epidemiologic studies estimate an 
R0 value of 2.2 [6] for SARS-CoV-2. Due 
to the progressive spread of the virus to over 
110 countries, with more than 118,000 cases 
and over 4200 deaths, SARS-CoV-2 infec-
tion was declared a pandemic by WHO on 
March 11, 2020 [7].
IntroduCtIon
Since December 2019, an increasing num-
ber of cases of pneumonia of “unknown 
etiology” have been identified in Wuhan, a 
large city of 11 million people, in mainland 
China [1]. These patients were epidemiolog-
ically linked to Huanan Seafood Wholesale 
Market, where wild and live animals were 
sold and, on January 1, 2020, Wuhan Pub-
lic Health Authorities shut it down. A week 
later, on January 7, 2020, a new Betacoronavi-
rus was isolated from bronchoalveolar-lavage 
fluid samples of three patients with severe 
pneumonia. This virus was initially identified 
as “novel coronavirus 2019” (2019-nCoV) 
and the illness likely to have been caused by 
2019-nCoV was named “novel coronavirus 
infected pneumonia” (NCIP) [2]. On Feb-
ruary 11, 2020, the World Health Organi-
zation (WHO) announced a new name for 
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Abstract
Severe acute respiratory syndrome (“SARS-CoV-2”, previously provisionally named “2019 novel 
coronavirus” or “2019-nCoV”) disease (COVID-19) in China, at the end of 2019, resulted in 
a large global outbreak.
Among patients with pneumonia caused by SARS-CoV-2, fever is the most common symptom, 
followed by dry cough. Bilateral lung involvement with ground-glass opacities (GGOs) is the 
most common finding from computed tomography (CT) images of the chest.
At present, there are no specific antiviral drugs against SARS-CoV-2 infection for potential 
therapy of humans. Current treatments are mainly focused on symptomatic and respiratory 
support in patients with COVID-19. Preventive measures are the current strategy to limit 
the spread of cases.
The present report summarizes the point of the situation about this global emergency.
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EpIdEMIology
As of March 31, 2020, there have been 
750,890 cases of COVID-19 globally, with 
101,739 of those in Italy; there have been 
36,405 confirmed deaths globally with 
11,591 of those in Italy [8]. The Chinese 
Center for Disease Control and Prevention 
recently published the largest case series 
to date of COVID-19 in mainland China 
(72,314 cases, updated through February 
11, 2020). Among a total of cases records:
 y 44,672 were classified as “confirmed cases 
of COVID-19” (diagnosis based on posi-
tive viral nucleic acid test results on throat 
swab samples: 62%);
 y 16,186 as “suspected cases” (diagnosis 
based on symptoms and exposures only: 
22%);
 y 10,567 as “clinically diagnosed cases” 
(15%);
 y 889 “asymptomatic cases” (1.2%).
Most patients were 30 to 79 years of age 
(87%), 1% were aged 9 years or younger, 
and 3% were aged 80 years or older. Most 
cases were classified as mild (81%), 14% as 
severe, and 5% as critical. The overall case-
fatality rate (CFR) was 2.3% (1023 deaths 
among 44,672 confirmed cases). CFR was 
8% in the group aged 70-79 years and 14.8% 
in the group aged 80 years and older. No 
deaths were reported among mild and severe 
cases. The CFR was 49.0% among critical 
cases. CFR was elevated among those with 
preexisting comorbid conditions: 10.5% for 
cardiovascular disease, 7.3% for diabetes, 
6.3% for chronic respiratory disease, 6.0% 
for hypertension, and 5.6% for cancer [9,10].
ClInICAl fEAturEs
According to WHO, a confirmed case of 
COVID-19 is a person with laboratory con-
firmation of infection with SARS-CoV-2, 
irrespective of clinical signs or symptoms 
(Box 1) [11].
The symptoms of SARS-CoV-2 infection 
appear after an incubation period of ap-
proximately 5.2 days [12]. The main clinical 
manifestations of COVID-19 are fever (90% 
or more), dry cough (around 75%), and dys-
pnea (up to 50%). Other symptoms include 
headache, fatigue, sputum production, and 
hemoptysis. A small but significant subset 
has gastrointestinal symptoms [13-16]. The 
majority of infected people have uncom-
plicated or mild illness (81%), but some of 
them will develop severe illness (including 
dyspnea, respiratory frequency >30/min, 
blood oxygen saturation <93%, partial pres-
sure of arterial oxygen to fraction of inspired 
oxygen ratio <300, and/or lung infiltrates 
>50% within 24 to 48 hours), which requires 
oxygen therapy (14%). A minority of them, 
around 5%, will require intensive care unit 
(ICU) treatment (due to respiratory failure, 
septic shock, and/or multiple organ dysfunc-
tion or failure) (Box 2) [9,17].
The most common diagnosis in severe CO-
VID-19 patients is severe pneumonia [9].
The currently available data suggest that 
the most frequent abnormalities were lym-
Box 1. Definitions in COVID-19 [11]
Confirmed case
A confirmed case is a person with laboratory confirmation of infection with the COVID-19 virus, irrespective of 
clinical signs and symptoms
Probable case
A probable case is a suspected case for whom the report from laboratory testing for the COVID-19 virus is inconclusive
Suspected case
 y a patient with acute respiratory illness (that is, fever and at least one sign or symptom of respiratory disease, for ex-
ample, cough or shortness of breath) AND with no other etiology that fully explains the clinical presentation AND 
a history of travel to or residence in a country, area or territory that has reported local transmission of COVID-19 
disease during the 14 days prior to symptom onset
 y a patient with any acute respiratory illness AND who has been a contact of a confirmed or probable case of COVID-19 
disease during the 14 days prior to the onset of symptoms
 y a patient with severe acute respiratory infection (that is, fever and at least one sign or symptom of respiratory disease, 
for example, cough or shortness breath) AND who requires hospitalization AND who has no other etiology that fully 
explains the clinical presentation
Box 2. Clinical syndromes associated with COVID-19 in adult [17]
Mild illness
Uncomplicated upper respiratory tract viral infection may have non-specific symptoms such as fever, fatigue, cough 
(with or without sputum production), anorexia, malaise, muscle pain, sore throat, dyspnea, nasal congestion, or head-
ache. Rarely, patients may also present with diarrhea, nausea, and vomiting
Pneumonia
Pneumonia but no signs of severe pneumonia and no need for supplemental oxygen
Severe pneumonia
Fever or suspected respiratory infection, plus one of the following: respiratory rate >30 breaths/min; severe respiratory 
distress; or SpO2 ≤ 93% on room air
Acute respiratory distress syndrome (ARDS)
 y Onset: within 1 week of a known clinical insult or new or worsening respiratory symptoms
 y Chest imaging (radiograph, CT scan, or lung ultrasound): bilateral opacities, not fully explained by volume overload, 
lobar or lung collapse, or nodules
 y Origin of pulmonary infiltrates: respiratory failure not fully explained by cardiac failure or fluid overload. Need 
objective assessment (e.g. echocardiography) to exclude hydrostatic cause of infiltrates/edema if no risk factor present
 y Oxygenation impairment in adults:
 y Mild ARDS: 200 mmHg < PaO2/FiO2a ≤ 300 mmHg (with PEEP or CPAP ≥ 5 cmH2O, or non-ventilated)
 y Moderate ARDS: 100 mmHg < PaO2/FiO2 ≤ 200 mmHg (with PEEP ≥ 5 cmH2O, or non-ventilated)
 y Severe ARDS: PaO2/FiO2 ≤ 100 mmHg (with PEEP ≥ 5 cmH2O, or non-ventilated)
Sepsis
Life-threatening organ dysfunction caused by a dysregulated host response to suspected or proven infection. Signs of 
organ dysfunction include: altered mental status, difficult or fast breathing, low oxygen saturation, reduced urine out-
put, fast heart rate, weak pulse, cold extremities or low blood pressure, skin mottling, or laboratory evidence of coagu-
lopathy, thrombocytopenia, acidosis, high lactate, or hyperbilirubinemia
Septic shock
Persisting hypotension despite volume resuscitation, requiring vasopressors to maintain MAP ≥ 65 mmHg and serum 
lactate level > 2 mmol/L
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phopenia (35-75% of cases), increased values 
of C-reactive protein (75-93% of cases), lac-
tate dehydrogenase (27-92% of cases), eryth-
rocyte sedimentation rate (up to 85% of cases) 
and D-dimer (36-43% of cases), as well as low 
concentrations of serum albumin (50-98% of 
cases), and hemoglobin (41-50%) [18].
COVID-19 pneumonia is common. The 
early chest CT features are multiple patchy 
pure ground glass opacities (GGOs) or 
GGOs with consolidation in the peripheral 
zone of the lung, often with vascular thick-
ening and the crazy paving pattern, air bron-
chogram sign, or halo sign (Figure 1) [19].
Lung ultrasonography is useful to manage 
COVID-19 with respiratory involvement 
due to several characteristics: safety, repeat-
ability, absence of radiation, low cost, and 
point-of-care use. Chest CT may be per-
formed in cases where lung ultrasonography 
is not sufficient to answer the clinical ques-
tion. Using a 12-zone method, characteristic 
findings include thickening of the pleural 
line with pleural line irregularity, B lines in 
figure 1. Chest CT: 
early features of 
COVID-19 pneumonia. 
Multiple patchy pure 
ground glass opacities 
(GGOs) may be seen.
a variety of patterns including focal, multi-
focal, and confluent, consolidations in a va-
riety of patterns including multifocal small, 
non-translobar, and translobar with occa-
sional mobile air bronchograms [20].
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dIAgnosIs
Confirmation of cases of COVID-19 is 
based on real-time reverse transcription 
polymerase chain reaction (rRT-PCR). At 
minimum, respiratory material should be 
collected from the upper respiratory speci-
mens (nasopharyngeal and oropharyngeal 
swab or wash in ambulatory patients) and/
or from the lower respiratory specimens 
(sputum if produced and/or endotracheal 
aspirate or bronchoalveolar lavage in patients 
with more severe respiratory disease) [21].
trEAtMEnt
Nowadays, there is no evidence from ran-
domized clinical trials to support specific 
drug treatment against the new coronavirus 
in suspected or confirmed cases. Therefore, 
current treatments mainly focus on symp-
tomatic and respiratory support.
InfECtIon Control And 
prEVEntIon
The WHO recommend infection control 
interventions to reduce the general risk of 
transmission of acute respiratory infection 
with SARS-CoV-2, including avoiding 
close contact with people suffering from 
acute respiratory infections, frequent hand 
washing especially after direct contact with 
ill people or their environment, and avoid-
ing unprotected contact with farm or wild 
animals [22].
ConClusIons
The outbreak of SARS-CoV-2 is a clini-
cal threat to the general population and 
healthcare workers worldwide. Scientists 
have made progress in the characterization 
of the novel coronavirus but, at present, 
there is not a specific treatment. Preventive 
measures are the current strategy to limit 
the spread of cases.
Key Points
 y Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the 
current pandemic of coronavirus disease 2019 (COVID-19)
 y This new virus was first discovered in Wuhan, China
 y As of March 31, 2020, there have been 750,890 cases of COVID-19 globally
 y Because of the absence of vaccinations and effective drugs, current treatments mainly focus 
on symptomatic and respiratory support
 y The mainstays of prevention are avoiding contacts with people suffering from acute respi-
ratory infections and frequent hand washing
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